Group 1 - The top five gaining Chinese concept stocks at the close were: Zhengye Biology up 40.52%, China Recycling Energy up 25.42%, Zhongjin Ke Industrial up 21.48%, Antelope Holdings up 18.36%, and Mengyun Holography up 18.24% [1]

Core Viewpoint - Zhengye Biology (ZYBT) experienced a significant stock price increase of 20.82%, reaching $6.5 per share, with a total market capitalization of $308 million as of August 13 [1] Financial Performance - As of December 31, 2024, Zhengye Biology reported total revenue of 186 million RMB, reflecting a year-on-year decrease of 11.95% [1] - The company's net profit attributable to shareholders was 11.31 million RMB, showing a substantial decline of 64.04% year-on-year [1] Company Overview - Zhengye Biology Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]

Core Viewpoint - Zhengye Biology (ZYBT) experienced a stock price increase of 5.28% on August 12, reaching $5.485 per share, with a total market capitalization of $260 million [1]. Financial Performance - As of December 31, 2024, Zhengye Biology reported total revenue of 186 million RMB, reflecting a year-on-year decrease of 11.95% [1]. - The net profit attributable to the parent company was 11.31 million RMB, showing a significant decline of 64.04% compared to the previous year [1]. Company Overview - Zhengye Biology Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1]. - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1].

8月11日，正业生物(ZYBT)盘中上涨3.92%，截至22:01，报5.414美元/股，成交3264.0美元，总市值2.57 亿美元。 财务数据显示，截至2024年12月31日，正业生物收入总额1.86亿人民币，同比减少11.95%；归母净利润 1131.1万人民币，同比减少64.04%。 本文源自：金融界 作者：行情君 资料显示，正业生物控股有限公司是一家在开曼群岛注册成立的境外控股母公司,主要通过其境内实体 子公司吉林正业生物制品股份有限公司运营。其子公司主要专注于兽医疫苗的研究、开发、制造和销 售,重点是中华人民共和国的牲畜疫苗。 ...

Core Viewpoint - Zhengye Biology (ZYBT) experienced a stock price increase of 4.4% on August 8, reaching $5.69 per share, with a total market capitalization of $270 million [1]. Financial Performance - As of December 31, 2024, Zhengye Biology reported total revenue of 186 million RMB, reflecting a year-on-year decrease of 11.95% [1]. - The net profit attributable to the parent company was 11.31 million RMB, showing a significant decline of 64.04% year-on-year [1]. Company Overview - Zhengye Biology Holdings Limited is a Cayman Islands-registered holding company that primarily operates through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1]. - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1].

Core Insights - Zhengye Biological (ZYBT) experienced a 5.87% increase in stock price, reaching $5.77 per share with a total market capitalization of $273 million as of August 7 [1] - The company's total revenue for the year ending December 31, 2024, is projected to be 186 million RMB, reflecting a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company is expected to be 11.31 million RMB, showing a significant decline of 64.04% year-on-year [1] Company Overview - Zhengye Biological Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]

Core Insights - Zhengye Biological (ZYBT) experienced a 3.67% increase in stock price, reaching $5.65 per share with a total market capitalization of $26.8 million as of August 7 [1] - The company's total revenue for the year ending December 31, 2024, is projected to be 186 million RMB, reflecting a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company is expected to be 11.31 million RMB, showing a significant decline of 64.04% year-on-year [1] Company Overview - Zhengye Biological Holdings Limited is a Cayman Islands-registered holding company that operates primarily through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]

8月5日，正业生物(ZYBT)开盘上涨8.68%，截至21:30，报5.76美元/股，成交5.88万美元，总市值2.73亿 美元。 财务数据显示，截至2024年12月31日，正业生物收入总额1.86亿人民币，同比减少11.95%；归母净利润 1131.1万人民币，同比减少64.04%。 资料显示，正业生物控股有限公司是一家在开曼群岛注册成立的境外控股母公司,主要通过其境内实体 子公司吉林正业生物制品股份有限公司运营。其子公司主要专注于兽医疫苗的研究、开发、制造和销 售,重点是中华人民共和国的牲畜疫苗。 作者：行情君 本文源自：金融界 ...

Group 1 - The core viewpoint of the article highlights the recent stock performance of Zhengye Biological (ZYBT), which saw an increase of 4.91% to $5.56 per share, with a total market capitalization of $263 million as of August 5 [1] - Financial data indicates that Zhengye Biological's total revenue for the year ending December 31, 2024, is projected to be 186 million RMB, representing a year-on-year decrease of 11.95% [1] - The net profit attributable to the parent company is reported at 11.31 million RMB, reflecting a significant year-on-year decline of 64.04% [1] Group 2 - Zhengye Biological Holdings Limited is registered in the Cayman Islands and primarily operates through its domestic subsidiary, Jilin Zhengye Biological Products Co., Ltd. [1] - The subsidiary focuses on the research, development, manufacturing, and sales of veterinary vaccines, particularly for livestock in the People's Republic of China [1]

本文源自：金融界 作者：行情君 7月31日，正业生物(ZYBT)盘中上涨2.14%，截至22:09，报5.72美元/股，成交1.1万美元，总市值2.71亿 美元。 财务数据显示，截至2024年12月31日，正业生物收入总额1.86亿人民币，同比减少11.95%；归母净利润 1131.1万人民币，同比减少64.04%。 资料显示，正业生物控股有限公司是一家在开曼群岛注册成立的境外控股母公司,主要通过其境内实体 子公司吉林正业生物制品股份有限公司运营。其子公司主要专注于兽医疫苗的研究、开发、制造和销 售,重点是中华人民共和国的牲畜疫苗。 ...